Results 161 to 170 of about 187,458 (237)

Modulating the Binding Kinetics of Bruton's Tyrosine Kinase Inhibitors through Transition-State Effects. [PDF]

J Am Chem Soc
Bravo E, Li Y, Lin DY, Srinivasan B, Barone M, Li SX, DelloRusso F, Rahiyanath AS, Corrionero A, Alfonso P, Prendiville N, Kozakov D, Andreotti AH, Tonge PJ.   +13 more
europepmc   +1 more source

Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL [PDF]

, 2018
Bartlett, Nancy L.
core   +1 more source

Ability of Bruton’s Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling

Molecular Pharmacology, 2017
Andrew T. Bender, A. Gardberg, A. Pereira, Theresa L. Johnson, Yin Wu, R. Grenningloh, J. Head, F. Morandi, P. Haselmayer, L. Liu-Bujalski   +9 more
semanticscholar   +1 more source

Cost impact of Bruton's tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia. [PDF]

J Comp Eff Res
Kittai AS, Patel DA, Shafrin J, Zawadzki N, Shetty VS, Barqawi YK, Rhodes JM.   +6 more
europepmc   +1 more source

Bruton's Tyrosine Kinase (BTK) Mutations in Chronic Lymphocytic Leukemia (CLL): A Clinical View. [PDF]

Mediterr J Hematol Infect Dis
Molica S, Allsup D.
europepmc   +1 more source

Bruton's tyrosine kinase inhibitors in the treatment of multiple sclerosis. [PDF]

Postep Psychiatr Neurol, 2023
Shulga O, Chabanova A, Kotsiuba O.
europepmc   +1 more source

Considerations for the practical management of cardiovascular risk with Bruton's tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia. [PDF]

Oncologist
Lenihan D, Bloom M, Copeland-Halperin R, Fleming MR, Fradley M, O'Quinn R, Bhat SA.   +6 more
europepmc   +1 more source

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: Phase 2 trial results [PDF]

, 2018
et al,, Stockerl-Goldstein, Keith E, Vij, Ravi   +2 more
core   +1 more source

The role of microglia in multiple sclerosis: implications for treatment with Bruton's tyrosine kinase inhibitors. [PDF]

Front Immunol
Vermersch P, Airas L, Berger T, Deisenhammer F, Grigoriadis N, Hartung HP, Magyari M, Popescu V, Pozzilli C, Pugliatti M, Van Wijmeersch B, Zakaria M, Oreja-Guevara C.   +12 more
europepmc   +1 more source